Discovering new CDK2 inhibitors by molecular docking and drug-likeness-based virtual screening for potential anticancer uses.
Worldwide, cancer ranks as the second most lethal disease. There are several potential anticancer therapeutic targets, but CDK2 stands out. Not many third-generation CDK2 inhibitors targeting the kinase domain have made it to market yet, but there are plenty of first- and second-generation inhibitor...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Árabe |
| Cyhoeddwyd: |
Egyptian Russian University
2024-10-01
|
| Cyfres: | ERU Research Journal |
| Pynciau: | |
| Mynediad Ar-lein: | https://erurj.journals.ekb.eg/article_351728_db17859d93dee0c5684bb90496169c46.pdf |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|